ClinicalTrials.gg
WithdrawnNCT02763761Updated Oct 9, 2018

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

A Phase 2 interventional study of Infliximab + Prednisone and Methylprednisolone + Prednisone in Renal Cell Carcinoma, Melanoma and Lung Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Insufficient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.

Enrollment
33rd of 33
0 · median 119
Started
2016
with 3 others
Phase 2
7 of 42
none open now
Registered
17th of 42
by date

Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is the 33rd largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2016, is one of 7 in phase 2, and was the 17th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4 diarrhea for up to 3 days or persistent Grade 2 diarrhea for more than 5 days after treatment with Yervoy and/or Opdivo

03

Conditions studied

  • Renal Cell Carcinoma
  • Melanoma
  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Subjects must have melanoma or lung cancer or renal cell carcinoma and received ipilimumab or nivolumab as a single treatment or in combination
  • Subject must have NCI common toxicity Grade 3-4 immune-related diarrhea for up to 3 days or persistent Grade 2 diarrhea for more than 5 days
  • Subjects must be discontinued from ipilimumab or nivolumab as monotherapy or with the combination regimen

Exclusion criteria

Exclusion Criteria:

  • Subjects who received other anti Cytotoxic T-lymphocytic antigen () (non-ipilimumab) or other anti-Programmed death-1 (PD-1) (non-nivolumab) treatment
  • Subjects treated with systemic (CST) within 1 week before randomization and subjects treated with infliximab within 7 weeks before randomization
  • Subjects with known history of tuberculosis
  • Subjects with disease that require use of systemic steroids or immunosuppressive treatment
  • Subjects allergic to infliximab, inactive components of infliximab, murine proteins and methylprednisolone

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Infliximab + Prednisone

    Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days

    Drug: Infliximab + Prednisone

  • Experimental
    Methylprednisolone + Prednisone

    Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days

    Drug: Methylprednisolone + Prednisone

Interventions

  • DrugInfliximab + Prednisone

    Drug pages: Infliximab · Prednisone

    Prednisone dose will be decreased every 3 days for 18 days

  • DrugMethylprednisolone + Prednisone

    Drug pages: Methylprednisolone · Prednisone

    Prednisone dose will be decreased every 4 days for 40 days

This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Improvement in management of immune related grade 3 and 4 diarrhea as measured by proportion of responders to less than or equal to grade 1

    Time frame: Up to 78 hours

  2. Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1

    Time frame: Up to 78 hours

Secondary outcomes

  1. Number of days to improvement to less than grade 1 diarrhea

    Time frame: Randomization up to 12 weeks

  2. Quality of life as measured by European Quality of Life-5 Dimensions Questionnaire (EQ-5D)

    Time frame: Up to 12 weeks

  3. Number of hospitalizations

    Time frame: Up to 12 weeks

  4. Duration of hospitalizations

    Time frame: Up to 12 weeks

  5. Number of patients with adverse events (AEs)

    Time frame: Up to 12 weeks

  6. Number of patients with AEs related to steroid use

    Time frame: Up to 12 weeks

  7. Number of patients with Gastrointestinal (GI) specific AEs

    Time frame: Up to 12 weeks

07

Study locations

10 sites
  • University of California Los Angeles
    Los Angeles, California 90024, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322-1013, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Atlantic Health System
    Morristown, New Jersey 07962, United States
  • Local Institution
    Albuquerque, New Mexico 87131, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Huntsman Cancer Institute at The University of Utah
    Salt Lake City, Utah 84112, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2016 (actual). Primary completion is estimated for Mar 2017, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2016
First posted
May 5, 2016
StartActual
Aug 16, 2016
Primary completionEst.
Mar 31, 2017
CompletionEst.
Mar 31, 2017
Last update
Oct 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02763761
Responsible party
Sponsor
First posted
May 5, 2016
Start date
Aug 16, 2016
Primary completion
Mar 31, 2017 (estimated)
Completion
Mar 31, 2017 (estimated)
Last update
Oct 9, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Prednisone · Methylprednisolone

Start the discussion